About Us
WHO WE ARE
We are a portfolio biopharmaceutical company based in the UK and USA. We translate breakthroughs in biology and basic medical research into innovative new medicines. With over 20 active therapeutic programs, five of which are in development, we are building a large, diversified portfolio of novel therapeutics with uncorrelated risk.
We are a team of industrially-seasoned drug discoverers, drug developers, and related roles. Together we are building a large and diversified portfolio of novel therapeutics with uncorrelated risk in a highly capital efficient manner.
OUR APPROACH
Our central premise since our inception in 2016 is that breakthroughs in the basic medical research required to create innovative new medicines are best found in the world’s top universities. However, translating these breakthroughs into new medicines is an industrial undertaking.
We match our world-class industrial drug discovery and drug development capabilities with basic medical breakthroughs made at our top university partners to create important new medicines.
We also in-license or acquire clinical-stage programs where we have unique insights and synergies arising from our discovery and preclinical activities to further accelerate the growth of our portfolio.
Our therapeutic programs are based on ideas, discoveries and inventions made by some of the top biomedical scientists in the world. We bring state-of-the-art industrial drug discovery and development expertise and capabilities to translate these breakthroughs into first-in-class and/or best-in-class new medicines to treat serious diseases.
We have no pre-set requirements for when we collaborate with academic inventors. We often collaborate very early, prior to patents, publications or lead molecules. It is the quality of the idea and the strength of the supporting evidence that counts.
OUR STRATEGY
Our strategy is based on four core pillars:
DIFFERENTIATED SCIENTIFIC ACCESS
We have a scalable R&D platform for the evergreen discovery and development of new medicines. This is enabled by an unprecedented level of access to breakthroughs in biology and basic medical research made at six of the world’s leading universities and research institutes with whom we are partnered (University of Cambridge, University of Oxford, Imperial College London, University College London, Kings College London, The Institute of Cancer Research).
We also in-license or acquire clinical-stage programs where we have unique insights and synergies arising from our discovery and preclinical activities to further accelerate the growth of our portfolio.
PORTFOLIO MODEL
We are developing a large and diversified pipeline of novel therapeutics with uncorrelated risk. We focus on programs that have the potential to be first-in-class and/or best-in-class in major commercial markets.
CAPITAL EFFICIENCY
We are developing a large and diversified portfolio of novel therapeutics with uncorrelated risk. This is a capital intensive undertaking and it is essential that we are highly capital efficient in all that we do. There are many design decisions behind our company that drive capital efficiency.
EXCELLENCE IN DECISION-MAKING
How we make decisions is a core component of our strategy, especially with respect to our portfolio and which programs we choose to progress and which we do not. There are many design decisions behind our company that facilitate excellence in decision-making.